GlassScriptPhysician profile
Sajid Ahmed
NPI 1497858591
$1,742.45
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $511 · 2020: $102 · 2021: $388 · 2022: $109 · 2023: $545 · 2024: $87.08.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $263.53 | 2019-2020 | |
| Foundation Medicine, INC. | $158.95 | 2021 | |
| Pfizer INC. | $132.29 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $125.94 | 2022-2023 | Libtayo |
| Daiichi Sankyo INC. | $114.10 | 2021-2024 | Enhertu, Injectafer |
| Novartis Pharmaceuticals Corporation | $99.97 | 2020-2023 | |
| Glaxosmithkline, LLC. | $99.49 | 2021-2023 | Ojjaara, Shingrix |
| Eisai INC. | $87.34 | 2019-2022 | |
| Genentech USA, INC. | $83.85 | 2019-2023 | Venclexta |
| Celgene Corporation | $77.28 | 2021-2023 | |
| Amgen INC. | $77.14 | 2019-2023 | Lumakras |
| Genzyme Corporation | $56.46 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $45.55 | 2021-2023 | Opdivo |
| Abbvie INC. | $41.93 | 2022-2024 | |
| Kite Pharma, INC. | $41.70 | 2021-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $40.31 | 2019 | |
| Terumo Bct, INC. | $36.36 | 2019 | |
| Gilead Sciences, INC. | $33.85 | 2021-2023 | Trodelvy |
| Emd Serono, INC. | $22.79 | 2023 | Tepmetko |
| Exelixis INC. | $19.54 | 2024 | Cabometyx |
| Immunomedics, INC. | $16.73 | 2020 | |
| Organon LLC | $15.93 | 2021 | |
| Array Biopharma INC | $15.69 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.81 | 2019 | |
| Seagen INC. | $11.68 | 2022 | |
| Merck Sharp & Dohme LLC | $11.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajid Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.